Introduction {#S1}
============

Cognitive deficits are core features of schizophrenia that are already evident at early phases of the illness ([@B1], [@B2]), with more than 80% of patients showing deficits in one or more domains of cognitive function ([@B3]). There are, however, noticeable differences among patients, with a subgroup showing severe and debilitating cognitive dysfunctions, typical of Kraepelin's description of dementia praecox ([@B4]), and other subgroup considered to be "neuropsychologically normal" ([@B5]). These distinguishable subgroups probably lie at different levels of severity on a continuum of causes or of different factors that might be influencing outcome ([@B6]).

Cognitive functioning has been associated with measures of brain structures both in schizophrenia patients and healthy subjects ([@B7]). It is now well established that schizophrenia is also associated with structural brain abnormalities ([@B8], [@B9]). Although some longitudinal magnetic resonance imaging (MRI) studies have reported a progressive brain tissue loss during the early years after the first psychotic episode of schizophrenia compared to healthy subjects ([@B10]--[@B12]), others have failed to reveal such progressive brain volume loss ([@B13]--[@B18]). Nevertheless, only few studies have examined those brain abnormalities that characterize the disorder in cognitive subgroups and, to the best of our knowledge, there are no previous studies that have examined progressive brain changes associated with cognitive deficit in schizophrenia.

The aim of this study was to identify neuroanatomical differences that possibly underlie neurocognitive function deficit in first-episode psychosis (FEP) patients followed up for 3-years. Previous studies have associated white matter abnormalities with cognitive deficit ([@B19], [@B20]). Perez-Iglesias and colleagues ([@B19]), using diffusion tensor imaging, showed that deficits in executive and motor functioning in patients with FEP were associated with reductions in white matter integrity, and Wexler et al. ([@B20]) found that neuropsychologically impaired patients had significantly smaller white matter volumes in several regions. On the basis of these studies, we hypothesized that patients with cognitive deficit would present a white matter volume diminution.

Materials and Methods {#S2}
=====================

Study design and setting {#S2-1}
------------------------

Data for the present investigation were obtained from a large epidemiological and 3-year longitudinal intervention program of FEP (PAFIP) conducted at the outpatient clinic and the inpatient unit at the University Hospital Marques de Valdecilla, Santander, Spain. It conformed to international standards for research ethics and was approved by the local institutional review board. Informed consent of the participants was obtained after the nature of the procedures had been fully explained. The referrals to the PAFIP came from the inpatient unit and emergency room at the University Hospital Marques de Valdecilla, community mental health services and other community health care workers in Cantabria. A more detailed description of our program has been previously reported ([@B21], [@B22]).

Subjects {#S2-2}
--------

All the patients included in PAFIP from February 2001 to December 2007 were invited to participate in this study. Patients referred to the program were selected if they met the following criteria: (1) 15--60 years; (2) living in the catchment area; (3) experiencing their first-episode of psychosis; (4) no prior treatment with antipsychotic medication or, if previously treated, a total life time of adequate antipsychotic treatment of less than 6 weeks; (5) DSM-IV criteria for brief psychotic disorder, schizophreniform disorder, schizophrenia, or schizoaffective disorder. Patients were excluded for any of the following reasons: (1) meeting DSM-IV criteria for drug dependence, (2) meeting DSM-IV criteria for mental retardation, (3) having a history of neurological disease or head injury. Our operational definition for a "first-episode of psychosis" included individuals with a non-affective psychosis (meeting the inclusion criteria defined above) who have not received previously antipsychotic treatment regardless the duration of psychosis. Individuals who entered the study received extensive clinical and psychopathological assessments and were examined by MRI scan. Only those patients who had a baseline neuropsychological assessment and completed both baseline and 3-year follow-up MRI scans were included in this study. Thus, 59 patients with a schizophrenia-spectrum disorder (schizophrenia *N* = 37, 62.7%; schizophreniform disorder, *N* = 15, 25.4%; schizoaffective disorder, *N* = 2, 3.4%; brief psychotic disorder, *N* = 2, 3.4%; not otherwise specified psychosis, *N* = 3, 5.1%) were included in the study.

The diagnoses were confirmed using the Structured Clinical Interview for DSM-IV (SCID-I) ([@B23]) carried out by an experienced psychiatrist 6 months after the baseline visit.

A group of healthy subjects (*N* = 43) who had no current or past history of psychiatric illness, including substance dependence, neurological or general medical disorders, as determined by using an abbreviated version of the Comprehensive Assessment of Symptoms and History (CASH) ([@B24]), was recruited from the local area. The controls underwent the same cognitive battery as the patients. After a detailed description of the study, each healthy subject gave their written informed consent to participate, in accordance with the local ethics committee ([@B25]).

There were no significant differences in a variety of variables (e.g., age at baseline, age of onset, academic level, alcohol, cannabis, or tobacco consumption, duration of untreated psychosis (DUP), duration of untreated illness (DUI), or symptomatology factors) between patients who were and those who were not included in the final analysis (all *p* \> 0.236).

Clinical assessment {#S2-3}
-------------------

Clinical symptoms were assessed by using the Brief Psychiatric Rating Scale total (BPRS) ([@B26]), the Scale for the Assessment of Negative Symptoms (SANS) ([@B27]), and the Scale for the Assessment of Positive Symptoms (SAPS) ([@B28]). We also divided psychopathology into three dimensions of symptoms: positive (scores for hallucinations and delusions), disorganized (scores for formal thought disorder, bizarre behavior, and inappropriate affect), and negative (scores for alogia, affective flattening, apathy, and anhedonia) ([@B29]).

Premorbid and sociodemographic variables {#S2-4}
----------------------------------------

Premorbid and sociodemographic information was recorded from patients, relatives, and medical records. Age of onset of psychosis was defined as the age when the emergence of the first continuous (present most of the time) psychotic symptom occurred. DUI was defined as the time from the first unspecific symptoms related to psychosis (for such a symptom to be considered, there should be no return to previous stable level of functioning) to initiation of adequate antipsychotic drug treatment. DUP was defined as the time from the first continuous (present most of the time) psychotic symptom to initiation of adequate antipsychotic drug treatment. Information about alcohol, cannabis, and tobacco consume were converted into binary variables coding for either the presence or absence of use.

Medication assessment {#S2-5}
---------------------

The amount and type of medication being prescribed during the 3-year follow-up period was thoroughly recorded. Patients were randomized as part of an intervention program out of the scope of the present study. After written informed consent was obtained, patients were randomly assigned to Haloperidol (*N* = 8), Olanzapine (*N* = 12), Risperidone (*N* = 12), Quetiapine (*N* = 8), Ziprasidone (*N* = 10), and Aripiprazole (*N* = 9). At 3-year follow-up patients were on: Haloperidol (*N* = 3), Olanzapine (*N* = 8), Risperidone (*N* = 12), Quetiapine (*N* = 5) Ziprasidone (*N* = 4), Aripiprazole (*N* = 8), Amisulpride (*N* = 1), Clozapine (*N* = 2), and Risperidone depot (*N* = 4). Eight patients withdrew from the medication, 27 patients switched their medication during follow-up period, and 2 were taking more than one antipsychotic at the time of follow-up MRI. No reliable information on medication intake was available for four patients. Additional information about concomitant medications is available under request.

Neuropsychological assessment {#S2-6}
-----------------------------

For the present study, baseline neuropsychological assessment was considered in both groups, patients, and normal control subjects. Baseline patients' assessment was carried out when clinical status permitted in order to maximize cooperation, and occurred at a mean of 10.5 weeks after intake followed by assessment after 3 years. They were never assessed during a period of clinical exacerbation. A detailed description has been reported elsewhere ([@B1]).

For the analysis in this study a subset of measures was selected to assess eight major cognitive domains: (1) for measuring verbal memory we used the Rey Auditory Verbal Learning Test \[RAVLT ([@B30])\], delayed recall; (2) for measuring visual memory we used Rey Complex Figure \[RCF ([@B31])\], delayed reproduction; (3) for measuring executive functions we used Trail Making Test \[TMT ([@B32])\], time to complete TMT-B; (4) for measuring working memory we used the Backward Digits scale \[WAIS III ([@B33])\], total subscore; (5) for measuring speed of processing we used WAIS III subtest Digit Symbol, standard total score; (6) for motor dexterity we used Grooved Pegboard Handedness ([@B34]), time to complete with dominant hand; (7) for measuring attention we used Continuous Performance Test \[CPT ([@B35])\], total number of correct responses; (8) The WAIS III subtest of Vocabulary was used as measure of premorbid IQ ([@B34]), standard total score.

In order to calculate a measure of Global Cognitive Functioning (GCF), raw cognitive scores were reversed when appropriate before standardization so they all have the same direction (the higher, the better). According to previous methodology ([@B36]), the GCF was calculated as *T*-scores (mean = 50, SD = 10) with raw scores of the healthy comparison sample. *T*-scores were converted to deficit scores that reflect presence and severity of cognitive deficit. Deficit scores on all tests were then averaged to create the GCF, which according to Keefe and colleagues deficit criterion ([@B37]), was dichotomized into two patients' subgroups: "deficit" (GCF \<1) and "non-deficit" (GCF ≥1) \[see Ref. ([@B6]) for details\].

MRI data acquisition {#S2-7}
--------------------

A multimodal MRI protocol \[T1, T2, and proton density (PD) sequences\] was acquired at the University Hospital Marques de Valdecilla, Santander, Spain, using a 1.5-T General Electric SIGNA System (GE Medical Systems, Milwaukee, WI, USA). This multimodal approach was designed to optimize discrimination between gray matter, white matter, and cerebrospinal fluid. The T1-weighted images, using a spoiled grass (SPGR) sequence, were acquired in the coronal plane with the following parameters: echo time (TE) = 5 ms, repetition time (TR) = 24 ms, number of excitations (NEX) = 2, rotation angle = 45°, field of view (FOV) = 26 cm × 19.5 cm, slice thickness = 1.5 mm, and a matrix of 256 × 192. The PD and transverse relaxation time (T2)-weighted images were obtained with the following parameters: 3.0 mm thick coronal slices, TR = 3000 ms, TE = 36 ms (for PD) and 96 ms (for T2), NEX = 1, FOV = 26 cm × 26 cm, matrix = 256 × 192. The in-plane resolution was 1.016 mm × 1.016 mm. MRIs of patients and controls were evenly acquired during follow-up time.

Image processing {#S2-8}
----------------

Processing of the images after acquisition was done by using a family of software programs called BRAINS2 ([@B38], [@B39]). The T1-weighted images were spatially normalized and resampled to 1.0-mm^3^ voxels so that the anterior-posterior axis of the brain was realigned parallel to the anterior commissure/posterior commissure line and the interhemispheric fissure aligned on the other two axes. The T2- and PD-weighted images were then aligned to the spatially normalized T1-weighted image. These images were then subjected to a linear transformation into standardized stereotaxic Talairach atlas space to generate automated measurements of frontal, temporal, parietal, and occipital lobes and also the cerebellum and subcortical regions ([@B39]). To further classify tissue volumes into gray matter, white matter, and CSF, we used a discriminant analysis method of tissue segmentation based on automated training class selection that utilized data from the T1-weighted, T2-weighted, and PD sequences ([@B40]). The discriminant analysis method permits to identify the range of voxel intensity values that characterize GM, WM, and CSF. An 8 bit number is assigned to each voxel indicating its partial volume tissue content (10--70 for CSF, 70--190 for GM, and 190--250 for WM). In this study we examined the volumes of whole brain (WB), whole brain gray matter (WBGM), whole brain white matter (WBWM), cortical CSF (CCSF), and lateral ventricles (LV), gray and white matter volumes of cortical (occipital, parietal, temporal, and frontal lobes) and subcortical (caudate nucleus and thalamus) regions volume. Caudate and thalamus were delineated using a reliable and validated semiautomated artificial neural network ([@B41]). The procedure for measuring the volume of caudate and thalamus are explained in detail in previous studies ([@B42], [@B43]).

Statistical analysis {#S2-9}
--------------------

The Statistical Package for Social Science, version 19.0 (SPSS Inc., Chicago, IL, USA), was used for statistical analyses. Significance was determined at the 0.05 level.

To examine brain volumetric differences between neurocognitive subgroups (no deficit vs. deficit) at baseline and 3-year follow-up, 1-way ANCOVA was performed. In each general linear model, the dependent measures were MRI volumes and the independent measure was group (no deficit vs. deficit). To test the hypothesis that the two groups would result in different progressive brain volume changes, repeated-measures analysis of covariance (repeated-measures ANCOVA) was performed for each ROI variable. The between-subject factor was group (no deficit vs. deficit) and the within subject factor was time (baseline and 3 year). Effects of time by group (interaction effect) were examined. Age, ICV, and premorbid IQ were included as covariates. There were no differences between groups related to age and ICV. However, there was a wide age range in our sample and the use of these two variables has been suggested in brain volume studies ([@B44]). The sample size (*n* = 59) provided sufficient power (\>80%) to detect large effect sizes (*d*~Cohen~ \> 0.8) but was underpowered (45%) to detect weak or modest effects (*d*~Cohen~ \< 0.5).

Pearson correlation coefficients with age, ICV, and IQ as covariates were used to investigate possible statistical relationships between brain volume and GCF.

A prior directional hypothesis had been made for the brain measure analyses, thereby lessening the need for Bonferroni corrections. The analyses examining the relationships between brain measures and GCF were performed without prespecified hypotheses, and therefore Bonferroni adjustments were applied.

Results {#S3}
=======

Demographic and clinical data are shown in Table [1](#T1){ref-type="table"}. Neuropsychological baseline assessment showed that of the 59 patients included in the study, 30 (50.8%) presented general neurocognitive deficit. There were no statistically significant differences in relevant demographic and clinical characteristics between patients with neurocognitive deficit (*N* = 30) and patients without it (*N* = 29) at baseline (Table [1](#T1){ref-type="table"}). However, the general neurocognitive deficit group showed a significant higher BPRS total score and greater severity of positive (SAPS total and positive dimension) and disorganized (scores for formal thought disorder, bizarre behavior, and inappropriate affect) symptoms at follow-up.

###### 

**Sociodemographic and clinical characteristics of the two neurocognitive groups of patients**.

  Characteristics                                    Non-deficit (*N* = 29)   Deficit (*N* = 30)   Statistics
  -------------------------------------------------- ------------------------ -------------------- ----------------------------------
  Age at initial MRI, mean (SD), years               28.50 (6.93)             32.12 (9.97)         *F*(1, 57) = 2.59, *p* = 0.113
  ICV, mean (SD)                                     1367.41 (128.78)         1343.19 (120.18)     *F*(1, 57) = 0.56, *p* = 0.458
  Males, *N* (%)                                     18 (62.1)                20 (66.7)            χ^2^(1) = 1.36, *p* = 0.712
  Time between scans, mean (SD), (range) days        1117.96 (39.58)          1120.63 (56.34)      *F*(1, 57) = 0.04, *p* = 0.835
  Right-handed, *N* (%)                              26 (89.7)                25 (83.3)            χ^2^(1) = 0.50, *p* = 0.478
  Parental socioeconomic status, mean (SD)           3.45 (0.87)              3.60 (0.89)          *F*(1, 57) = 0.44, *p* = 0.512
  Years of study, mean (SD)                          10.89 (3.17)             10.13 (3.19)         *F*(1, 57) = 0.85, *p* = 0.360
  Alcohol users, *N* (%)                             17 (58.6)                19 (63.3)            χ^2^(1) = 1.38, *p* = 0.711
  Cannabis users, *N* (%)                            15 (51.7)                11 (36.7)            χ^2^(1) = 1.35, *p* = 0.244
  Tobacco users, *N* (%)                             17 (58.6)                16 (53.3)            χ^2^(1) = 0.17, *p* = 0.683
  Age at onset, mean (SD), years                     27.61 (6.28)             30.59 (9.79)         *F*(1, 57) = 1.91, *p* = 0.172
  DUP mean, (SD), (median), months                   10.74 (19.39)            18.35 (21.15)        *F*(1, 57) = 2.07, *p* = 0.155
  DUI mean, (SD), (median), months                   28.32 (32.79)            30.45 (29.54)        *F*(1, 57) = 0.07, *p* = 0.794
  SANS at intake, mean (SD)                          6.55 (4.95)              7.13 (5.37)          *F*(1, 57) = 0.19, *p* = 0.667
  SANS at follow up, mean (SD)                       1.89 (2.96)              3.34 (4.57)          *F*(1, 55) = 2.00, *p* = 0.162
  SAPS at intake, mean (SD)                          13.44 (4.44)             13.67 (4.17)         *F*(1, 57) = 0.04, *p* = 0.846
  SAPS at follow up, mean (SD)                       0.57 (1.40)              2.86 (4.62)          ***F(1, 55) = 6.30, p = 0.015***
  BPRS at intake, mean (SD)                          62.00 (11.67)            63.50 (13.68)        *F*(1, 57) = 0.21, *p* = 0.653
  BPRS at follow-up, mean (SD)                       27.14 (4.33)             32.93 (14.17)        ***F(1, 55) = 4.28, p = 0.043***
  **SYMPTOM DIMENSIONS TOTAL SCORES AT BASELINE**                                                  
  Negative (mean) (SD)                               4.75 (4.69)              5.40 (4.90)          *F*(1, 57) = 0.26, *p* = 0.610
  Disorganized (mean) (SD)                           6.07 (3.43)              6.10 (3.35)          *F*(1, 57) \< 0.01, *p* = 0.972
  Psychotic (mean) (SD)                              7.37 (2.38)              7.57 (2.31)          *F*(1, 57) = 0.09, *p* = 0.760
  **SYMPTOM DIMENSIONS TOTAL SCORES AT FOLLOW UP**                                                 
  Negative (mean) (SD)                               1.54 (2.33)              2.90 (4.25)          *F*(1, 55) = 2.23, *p* = 0.141
  Disorganized (mean) (SD)                           0.25 (0.84)              1.45 (2.99)          ***F(1, 55) = 4.16, p = 0.046***
  Positive (mean) (SD)                               0.32 (1.19)              1.41 (2.06)          ***F(1, 55) = 5.95, p = 0.018***

BPRS, brief psychiatric rating scale; DUP, duration of untreated psychosis; DUI, duration of untreated illness; ICV, intracranial volume; SANS, scale for the assessment of negative symptoms; SAPS, scale for the assessment of positive symptoms; SD, standard deviation. Bold values were statistically significant (*p* \< 0.05).

Neuropsychological data is presented in Table [2](#T2){ref-type="table"}. The general neurocognitive deficit group had worse premorbid IQ, and showed consistently greater deficits all over cognitive domains. Worse executive function, poor motor dexterity, and particularly attentional deficits marked the more severely deficit patients.

###### 

**Comparison of neurocognitive groups on neuropsychological variables (*Student's t-*distribution with 58 degrees of freedom)**.

  Characteristics      Non-deficit (*N* = 29)   Deficit (*N* = 30)   Statistics
  -------------------- ------------------------ -------------------- --------------------------
  Premorbid IQ         −0.08 (1.13)             −1.03 (1.19)         *t* = 3.07, *p* = 0.003
  Attention            −0.39 (1.5)              −4.41 (5.31)         *t* = 3.98, *p* \< 0.001
  Verbal memory        −0.73 (1.08)             −1.31 (1.08)         *t* = 2.04, *p* = 0.046
  Visual memory        −0.47 (1.1)              −1.16 (1.09)         *t* = 2.41, *p* = 0.019
  Working memory       −0.23 (0.51)             −0.84 (0.75)         *t* = 3.66, *p* = 0.001
  Executive function   −0.21 (0.74)             −2.51 (2.56)         *t* = 4.72, *p* = 0.001
  Processing speed     −1.02 (1.15)             −2.02 (0.89)         *t* = 3.75, *p* = 0.001

Brain volumes at baseline in FEP subjects are presented in Table [3](#T3){ref-type="table"}. There were no significant differences between neuropsychological subgroups in any of the brain regions studied at baseline \[all *F*(1, 54) ≤ 3.42; all *p* ≥ 0.070\] and follow-up \[all *F*(1, 54) ≤ 3.43; all *p* ≥ 0.07\] time points (Table [3](#T3){ref-type="table"}). Patients with cognitive deficit showed overall lower gray and white matter volumes but these differences did not reach statistical significance.

###### 

**Comparison of MRI brain volumes between deficit first-episode psychosis (FEP) and non-deficit FEP patients at baseline and follow-up and the group by time interaction**.

                          Basal     Follow-up                                                                                                                       
  ----------------------- --------- ----------- --------- -------- ------- -------- ------- --------- -------- --------- -------- ------- ------ ------- ---------- -----------
  Total brain tissue      1286.67   119.47      1254.77   118.32   2.5     1.41     0.240   1279.72   121.67   1234.12   126.45   3.6     3.43   0.070   2.07       0.156
  Frontal lobe tissue     430.55    38.56       420.36    37.69    2.4     0.48     0.491   425.51    41.05    412.32    44.88    3.1     0.37   0.543   0.00       0.958
  Parietal lobe tissue    249.22    25.11       246.06    26.62    1.3     0.14     0.710   248.9     22.44    241.94    27.67    2.8     0.55   0.463   **4.97**   **0.030**
  Temporal lobe tissue    227.87    25.25       219.23    22.37    3.8     1\. 51   0.225   225.39    26.89    215.74    23.09    4.3     2.03   0.160   0.28       0.599
  Occipital lobe tissue   121.17    16.74       120.6     17.72    0.5     0.34     0.560   122.92    15.42    118.56    17.42    3.5     0.09   0.768   2.06       0.157
  Total brain GM          779.42    72.43       759.18    87.63    2.6     0.52     0.473   768.1     66.92    738.61    85.42    3.8     0.41   0.523   **4.32**   **0.042**
  Frontal lobe GM         261.06    21.3        254       28.21    2.7     0.02     0.900   259.11    23.29    247.52    30.43    4.5     0.47   0.494   1.11       0.297
  Parietal lobe GM        137.43    15.61       135.92    19.78    1.1     1\. 58   0.214   135.82    13.62    131.81    18.55    3.0     0.04   0.837   3.72       0.059
  Temporal lobe GM        156.56    17.56       150.69    17.68    3.7     0.00     0.956   153.99    18.21    146.8     17.84    4.7     0.63   0.431   1.82       0.183
  Occipital lobe GM       63.2      9.84        63.44     10.33    -0.4    1.73     0.194   63.39     9.81     61.00     9.10     3.8     0.00   0.994   2.19       0.145
  Total brain WM          507.25    60.77       495.59    50.32    2.3     2.07     0.156   511.62    65.09    495.51    55.25    3.1     2.09   0.154   0.02       0.878
  Frontal lobe WM         169.49    21.67       166.37    18.31    1.8     1.06     0.308   166.4     21.36    164.8     20.15    1.0     0.18   0.677   0.15       0.230
  Parietal lobe WM        111.79    14.02       110.13    13.15    1.5     0.90     0.346   113.08    11.82    110.13    14.44    2.6     1.67   0.202   0.24       0.623
  Temporal lobe WM        71.31     11.89       68.55     8.91     3.9     3.42     0.070   71.39     12.56    68.94     8.44     3.4     1.77   0.189   1.43       0.237
  Occipital lobe WM       57.97     9.74        57.17     10.14    1.4     0.12     0.727   59.53     8.71     57.56     10.57    3.3     0.34   0.563   0.20       0.657
  Cortical CSF            44.84     18.02       50.44     22.5     -12.5   1.16     0.287   46.86     18.48    57.76     32.89    -23.3   2.52   0.118   0.71       0.404
  Lateral ventricles      14.73     6.84        14.14     6.15     4.0     0.46     0.501   14.82     7.81     14.79     7.47     0.2     0.15   0.703   0.38       0.543
  Thalamus                11.76     1.5         11.66     1.3      0.9     2.02     0.161   11.46     1.46     11.29     1.24     1.5     1.02   0.317   0.03       0.866
  Caudate                 5.37      0.76        5.25      0.75     2.2     0.22     0.642   5.24      0.75     5.11      0.77     2.5     0.10   0.750   0.52       0.476

CSF, cerebrospinal fluid; Diff, difference; GM, gray matter; WM, white matter, percent difference was calculated as 100 × (VolDeficit − VolNoDeficit)/VolNoDeficit. Bold values were statistically significant (*p* \< 0.05).

There was a significant time by group interaction for the parietal tissue volume \[*F*(1, 54) = 4.97, *p* = 0.030\], with the general neurocognitive deficit group showing a greater volume decrease (1.67%) than the non-deficit group (0.13%). Similarly, there was also a significant time by group interaction for the total gray matter volume \[*F*(1, 54) = 4.31, *p* = 0.042\], showing a greater reduction in the general neurocognitive deficit group (2.71%) than in the non-deficit group (1.45%) (see Figure [1](#F1){ref-type="fig"}). Interestingly, when the analyses were controlled by possible confounding variables (sex, DUP, tobacco, cannabis, and alcohol consumption) only the parietal lobe tissue showed a significant group by time interaction.

![**Total gray matter and parietal tissue volume in deficit and non-deficit first-episode psychosis patients**.](fpsyt-04-00134-g001){#F1}

No significant correlations between brain volume at baseline and GCF were found. At follow-up period, there were significant negative correlations between GCF and parietal tissue lobe (*r* = −0.29, *p* = 0.031) and temporal lobe gray matter (*r* = −0.27; *p* = 0.049). However, these correlations were weak and did not remain significant after correcting for multiple testing (Bonferroni correction).

Discussion {#S4}
==========

In the present study, a GCF index was calculated to identify schizophrenia patients who had general neurocognitive deficit at baseline ([@B6]). Contrary to our expectations, there were no brain volume differences between the cognitively impaired and cognitively preserved groups at any of the time-point studied. However, there were significant time by group interactions for the parietal tissue volume and the total gray matter volume, with the general neurocognitive deficit group showing a greater reduction in both regions during the 3-year follow-up interval. This is, to the best of our knowledge, the first study to examine progressive brain changes in schizophrenic cognitive deficit.

Neuropsychological assessment carried out at baseline indicated that 50.8% of the patients included in the study presented general neurocognitive deficit. These results are in full agreement with previous studies in FEP patients ([@B2]).

Only two previous cross-sectional studies ([@B20], [@B45]) have examined brain volume differences between cognitive subgroups in schizophrenia and their results have been inconclusive. Supporting our results, Ortiz-Gil and colleagues ([@B45]) did not find differences in lateral ventricular volume or WB volume between cognitively intact and cognitively deficit schizophrenia patients. Using Voxel-based morphometry, they also failed to detect significant difference in volumes of gray and white matter between those groups. However, Wexler et al. ([@B20]), using VBM to compare neuropsychology near normal and neuropsychology impaired subgroups, found that these groups differed significantly from each other in white matter volumes of the sensorimotor and parietal-occipital regions, with the neuropsychology impaired group showing smaller volumes in these brain regions. Nonetheless, it is of note that this VBM study did not adopt any statistical procedures to control for multiple comparisons. It is important to take into account that mean duration of illness among patients was above 18 years in both studies, while our patients had a shorter duration of illness (non-deficit: 28.32 months, deficit: 30.45 months).

Only cross-sectional studies have addressed the relationship between cognitive deficit and brain structure in schizophrenia. However, it has been suggested that this relationship may not be adequately assessed in a cross-sectional study ([@B45]). We found significant time by group interactions for the parietal tissue volume and the total gray matter volume, with the general neurocognitive deficit group showing a greater reduction in both regions (parietal tissue volume and the total gray matter volume) during the 3-year follow-up interval. In a recent study ([@B13]) we found that brain tissue volumes decrease in patients at early years after the first episode was similar to that found in healthy controls. Although several longitudinal studies in schizophrenia have described a greater degree of brain tissue volumes decrease in the early stage of the illness ([@B10]--[@B12]), others have failed to confirm these findings ([@B13]--[@B18]). For a review see Olabi et al. ([@B46]). Taken this together, we might speculate that the progressive brain volume loss found in schizophrenia might be associated with this general cognitive deficit patients' subgroup.

Limitations {#S4-10}
-----------

A uniform follow-up interval using the same MRI scanner and protocol, and a thorough clinical investigation during the follow-up period add strength to the conclusions drawn from this study. However, several limitations should be taken into account when interpreting the results of the current study. First, the diagnostic heterogeneity of the sample might bias our findings. Second, and given the fact that schizophrenia is a life-long disease, a follow-up period of 3 years may be too short to demonstrate other subtle changes. Third, analyses taking into account if neurocognitive function maintained, declined, or improved during follow-up could not be conducted because of the small sample size in our study. Fourth, a major confounding factor could be the intake of antipsychotic medication ([@B47]). Some studies have showed a relationship between antipsychotic medication use and longitudinal brain volume change in schizophrenia ([@B10], [@B48]), although others have failed to clearly demonstrate an influence of antipsychotic medication on brain volume change ([@B49]--[@B51]). Some patients withdrew from their medication, and most of them switched medication during the 3-year follow-up period, which makes the investigation of the effects of different types of antipsychotics an unfeasible study. Fifth, this study only measured a number of structures, and finally, brain volume changes in schizophrenia are subtle, so the sample size might be considered small to make any definitive assertions. While our data provided sufficient power to detect large effects, the detection of weak effects requires large study populations.

Conclusion {#S5}
==========

In conclusion, our results, based on a representative sample of first-episode schizophrenia-spectrum patients, do not confirm the presence of significant morphometric differences between cognitively impaired and cognitively preserved schizophrenia patients at the early stages of the illness. However, there were significant time by group interactions for the parietal tissue volume and the total gray matter volume during the 3-year follow-up period, which might indicate that cognitive deficit in schizophrenia would be associated with progressive brain volume loss. Further investigations are warranted to fully clarify the relationship between cognitive deficit and brain structure in schizophrenia.
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